ArticleSarcoma2011
Pathobiologic markers of the ewing sarcoma family of tumors: state of the art and prediction of behaviour.
Article in Sarcoma, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 81 citations in OpenAlex.
- From the Unexpected: Unveiling the Diverse Presentations of Extraosseous Ewing's Sarcoma.Cureus · 2025Article
- Primary intracranial extraosseous Ewing's sarcoma with intraspinal metastasis in children: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Abdominal distention, immunopositivity, and aggressive nature: A rare Ewing's sarcoma of the adrenal gland.Radiology case reports · 2024Article
- Suggested role for neutrophil extracellular trap formation in Ewing sarcoma immune microenvironment.Cancer science · 2024Article
- Article
- Practical Management of Adult Ultra-Rare Primary Retroperitoneal Soft Tissue Sarcoma: A Focus on Perivascular Epithelioid Tumours and Extraosseous Ewing Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Article
- Pediatric Patient with a Diagnosis of Pelvic Extraosseous Ewing's Sarcoma: A Case Report.Journal of the Belgian Society of Radiology · 2023Article
- Primary Ewing sarcoma of the liver: Diagnosis, management, and prognosis: A case report and literature review.Clinical case reports · 2022Article
- Ewing's sarcoma in scapula, epidemiology, clinical manifestation, diagnosis and treatment: A literature review.Annals of medicine and surgery (2012) · 2022Review
- Ewing sarcoma of the facial soft tissues-a case report.Journal of surgical case reports · 2022Article
- Anomalous chin lesion: The many presentations of extraosseous Ewing's sarcoma.Dental research journal · 2022Article
- The Landscape of Regulatory Noncoding RNAs in Ewing's Sarcoma.Biomedicines · 2021Review
- The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis.Cancers · 2021Review
- EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.Nucleic acids research · 2020Article
- Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers.Oncotarget · 2020Article
- Review
- Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment.Frontiers in oncology · 2020Review
- Ewing's sarcoma in the spinal canal of T12-L3: A case report and review of the literature.Oncology letters · 2019Article
- Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients.EBioMedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past three decades, the outcome of Ewing sarcoma family tumor (ESFT) patients who are nonmetastatic at presentation has improved considerably. The prognosis of patients with metastatic disease at the time of diagnosis and recurrence after therapy remains dismal. Drug-resistant disease at diagnosis or at relapse remains a major cause of mortality among patients diagnosed with ESFT. In order to improve the outcome for patients with potential relapse, there is an urgent need to find reliable markers that either predict tumor behaviour at diagnosis or identify therapeutic molecular targets at the time of recurrence. An improved understanding of the cell of origin and the molecular pathways that regulate tumorigenicity in ESFT should aid us in the search for novel therapies for ESFT. The purpose of this paper is thus to outline current concepts of sarcomagenesis in ESFT and to discuss ESFT patterns of differentiation and molecular markers that might affect prognosis or direct future therapeutic development.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.